Publicacións (565) Publicacións nas que participase algún/ha investigador/a

filter_list

2025

  1. Genetic Landscape of Patients With Dilated Cardiomyopathy and a Systemic Immune-Mediated Disease

    JACC: Heart Failure, Vol. 13, Núm. 1, pp. 133-145

  2. The Effect of Rehabilitation Therapy in Children with Intervened Congenital Heart Disease: A Study Protocol of Randomized Controlled Trial Comparing Hospital and Home-Based Rehabilitation

    Journal of Clinical Medicine, Vol. 14, Núm. 3

2024

  1. A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 10, Núm. 4, pp. 285-293

  2. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial

    JAMA Cardiology

  3. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    The New England journal of medicine, Vol. 390, Núm. 20, pp. 1849-1861

  4. Biallelic Loss of Function Variants in Myocardial Zonula Adherens Protein Gene (MYZAP) Cause a Severe Recessive Form of Dilated Cardiomyopathy

    Circulation: Heart Failure

  5. Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy

    Journal of the American Heart Association, Vol. 13, Núm. 21, pp. e036208

  6. Clinical Relevance of the Systematic Analysis of Copy Number Variants in the Genetic Study of Cardiomyopathies

    Genes, Vol. 15, Núm. 6

  7. Diagnosing transthyretin amyloidosis in patients with known genetic cardiomyopathies - opportunities and open questions. Response

    Revista Espanola de Cardiologia

  8. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 667-679

  9. Diagnosis of transthyretin amyloidosis in patients with established cardiomyopathy

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 347-349

  10. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  11. Double somatic mosaicism in Marfan syndrome

    American Journal of Medical Genetics, Part A, Vol. 194, Núm. 12

  12. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

  13. Electrophysiological Phenotype-Genotype Study of Sustained Monomorphic Ventricular Tachycardia in Inherited, High Arrhythmic Risk, Left Ventricular Cardiomyopathy

    Circulation: Arrhythmia and Electrophysiology, Vol. 17, Núm. 12, pp. e013145

  14. Emerging Themes in Genetics of Hypertrophic Cardiomyopathy: Current Status and Clinical Application

    Canadian Journal of Cardiology

  15. Founder effect of a common pathogenic TNNT2 variant responsible for hypertrophic cardiomyopathy in the northwest of Spain

    European Journal of Human Genetics, Vol. 32, Núm. S1, pp. P20.017.A

  16. Genetic basis of right and left ventricular heart shape

    Nature Communications , Vol. 15, Núm. 1

  17. Hypertrophic cardiomyopathy due to truncating variants in myosin binding protein C: A Spanish cohort

    Open Heart, Vol. 11, Núm. 2

  18. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831